• Entrada outlined a 2026 pipeline-heavy strategy in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), targeting multiple clinical readouts.
• ENTR-601-44 DMD Cohort 1 met its safety and tolerability objective at 6 mg/kg; no serious adverse events or discontinuations reported.
• Cohort 1 showed functional gains versus placebo in Time to Rise and Time to Rise Velocity; open-label data expected by year-end 2026.
• ENTR-601-45 Cohort 1 data expected mid-2026; broader DMD filings for ENTR-601-50 and ENTR-601-51 planned following ongoing study reviews.
• Vertex-run VX-670 DM1 study moved into multiple-ascending-dose testing with results expected in H2 2026; partnership includes up to USD 485 million milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.